Other
Penetrating Keratoplasty
0
Pipeline Programs↗
1
Active Trials↗
1
Companies Involved↗
Penetrating Keratoplasty is an early-stage landscape with 0 programs across 1 company. The most active players are Lux Biosciences, Inc..
Intelligence
Pipeline Metrics
Competitive Density
Pipeline Velocity
Mech. Concentration
Completion Rate
Attrition Rate
Competition
Competitive Landscape
Bubble size = clinical trials
Approved
Phase 3
Phase 2
Phase 1
Preclinical
Key Players
Top Companies Companies ranked by the number of pipeline programs they run for this disease.
Pipeline
Programs by Phase
No pipeline programs currently tracked for this disease.
Analysis
Trial Status
6
clinical trials
Completed3 · 50%
Terminated2 · 33%
Recruiting1 · 17%
Clinical Trials
Trial Activity
6 trials
Topical Infliximab in Eyes With Penetrating Keratoplasty
Recruiting·—·Phase 1/2·NCT05180994·50 enrolled
Immunosuppression During Penetrating Keratoplasty, Using a Subconjunctival Implant Releasing Dexamethasone : Tolerance and Safety Pilot Study
Completed·—·Phase 2·NCT02834260·14 enrolled
Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)